Celecoxib · oral capsule
NSAID
Approved uses
Acute pain in adults and primary dysmenorrhea
400 mg initially, followed by a further 200 mg if needed on the first day; thereafter 200 mg twice daily as required
A COX-2 selective NSAID, so it spares platelet function, which matters if bleeding risk is a concern
Osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis in patients 2 years and older, and ankylosing spondylitis
Osteoarthritis 200 mg once daily or 100 mg twice daily; rheumatoid arthritis 100 to 200 mg twice daily; ankylosing spondylitis 200 mg once daily or 100 mg twice daily, and if no effect is observed after 6 weeks, a trial of 400 mg daily may be worthwhile; juvenile rheumatoid arthritis 50 mg twice daily at 10 to 25 kg and 100 mg twice daily above 25 kg
Contraindications
- Known hypersensitivity, such as anaphylactic reactions or serious skin reactions, to celecoxib or any component of the drug product
- History of asthma, urticaria or other allergic-type reactions after taking aspirin or other NSAIDs, because severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients
- Use in the setting of coronary artery bypass graft (CABG) surgery
- Demonstrated allergic-type reactions to sulfonamides
50 mg (bottle of 60), 100 mg and 200 mg (bottles of 100 and 500, 100 unit dose), 400 mg (bottle of 60, 100 unit dose)
Celecoxib has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2. Celecoxib is a potent inhibitor of prostaglandin synthesis in vitro. Celecoxib concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Since celecoxib is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.
Warnings & Precautions
- Cardiovascular thrombotic events: NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. Celecoxib is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. Avoid use in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events.
- Gastrointestinal bleeding, ulceration, and perforation: NSAIDs cause an increased risk of serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk. If a serious GI adverse event is suspected, discontinue celecoxib until a serious GI adverse event is ruled out.
- Hepatotoxicity: Elevations of ALT or AST (three or more times the upper limit of normal) have been reported in approximately 1% of NSAID-treated patients in clinical trials, and rare, sometimes fatal, cases of severe hepatic injury have been reported. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash), discontinue celecoxib immediately and perform a clinical evaluation of the patient.
- Hypertension: NSAIDs, including celecoxib, can lead to new onset of hypertension or worsening of preexisting hypertension. Patients taking ACE inhibitors, thiazide diuretics or loop diuretics may have impaired response to these therapies. Monitor blood pressure during the initiation of NSAID treatment and throughout the course of therapy.
- Heart failure and edema: A meta-analysis showed an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated and nonselective NSAID-treated patients compared to placebo, and fluid retention and edema have been observed in some patients treated with NSAIDs. Avoid use in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.
- Renal toxicity: Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. When renal prostaglandins help maintain renal perfusion, an NSAID may reduce renal blood flow, which may precipitate overt renal decompensation. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function.
- Hyperkalemia: Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment.
- Anaphylactic reactions: Celecoxib has been associated with anaphylactic reactions in patients with and without known hypersensitivity to celecoxib and in patients with aspirin sensitive asthma. Celecoxib is a sulfonamide, and both NSAIDs and sulfonamides may cause allergic type reactions in certain susceptible people. Seek emergency help if any anaphylactic reaction occurs.
- Exacerbation of asthma related to aspirin sensitivity: Because cross-reactivity between aspirin and other NSAIDs has been reported, celecoxib is contraindicated in patients with aspirin-sensitive asthma. In patients with preexisting asthma without known aspirin sensitivity, monitor for changes in the signs and symptoms of asthma.
- Serious skin reactions: Erythema multiforme, exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), DRESS, acute generalized exanthematous pustulosis (AGEP) and fixed drug eruption have occurred with celecoxib. These events may occur without warning and can be fatal. Discontinue celecoxib at the first appearance of skin rash or any other sign of hypersensitivity. Celecoxib is contraindicated in patients with previous serious skin reactions to NSAIDs.
- Drug reaction with eosinophilia and systemic symptoms (DRESS): DRESS has been reported in patients taking NSAIDs, and some of these events have been fatal or life-threatening. It typically, although not exclusively, presents with fever, rash, lymphadenopathy, or facial swelling, and early signs such as fever or lymphadenopathy may be present even though rash is not evident. If such signs or symptoms are present, discontinue celecoxib and evaluate the patient immediately.
- Fetal toxicity: Avoid use at about 30 weeks gestation and later because of the risk of premature closure of the fetal ductus arteriosus. Use at about 20 weeks gestation or later may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Between about 20 and 30 weeks, limit use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours, and discontinue if oligohydramnios occurs.
- Hematologic toxicity: Anemia has occurred in NSAID-treated patients; if a patient has any signs or symptoms of anemia, monitor hemoglobin or hematocrit. NSAIDs, including celecoxib, may increase the risk of bleeding events, and coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs and SNRIs may increase this risk. Monitor these patients for signs of bleeding.
- Masking of inflammation and fever: The pharmacological activity of celecoxib in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections.
- Laboratory monitoring: Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically.
- Disseminated intravascular coagulation (DIC): Because of the risk of disseminated intravascular coagulation in pediatric patients with systemic onset JRA, monitor patients for signs and symptoms of abnormal clotting or bleeding, and inform patients and their caregivers to report symptoms as soon as possible.
Common Side Effects
The most common adverse reactions in arthritis trials (more than 2% and more than placebo) are abdominal pain, diarrhea, dyspepsia, flatulence, peripheral edema, accidental injury, dizziness, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection and rash. Dyspepsia and abdominal pain were among the most common reasons for discontinuation due to adverse events, cited in 0.8% and 0.7% of patients taking celecoxib, respectively.
Pregnancy: Avoid use at about 30 weeks of gestation and later because of the risk of premature closure of the fetal ductus arteriosus. Use at about 20 weeks gestation or later may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment, so limit dose and duration between about 20 and 30 weeks of gestation.
Lactation: Limited data show low levels of celecoxib in breast milk. Use caution in a nursing woman, and weigh the benefits of breastfeeding with the mother's clinical need for celecoxib and any potential adverse effects on the breastfed infant.
Celecoxib is approved for relief of the signs and symptoms of Juvenile Rheumatoid Arthritis in patients 2 years and older. Safety and efficacy have not been studied beyond six months in children.